Document is current
Any future updates will be listed below
-
Authors
Kundert, Kale https://orcid.org/0000-0003-0051-5867
Lucas, James E.
Watters, Kyle E. https://orcid.org/0000-0001-6858-6632
Fellmann, Christof https://orcid.org/0000-0002-9545-5723
Ng, Andrew H. https://orcid.org/0000-0001-8044-1807
Heineike, Benjamin M.
Fitzsimmons, Christina M.
Oakes, Benjamin L.
Qu, Jiuxin
Prasad, Neha
Rosenberg, Oren S. https://orcid.org/0000-0002-5736-4388
Savage, David F.
El-Samad, Hana
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
Kortemme, Tanja https://orcid.org/0000-0002-8494-680X
-
Funding
Funding for this research was provided by:
Post 9/11 GI Bill
Chan Zuckerberg Biohub
Howard Hughes Medical Institute
Paul Allen Frontiers Group Distinguished Investigator
W. M. Keck Foundation (n/a)
U.S. Department of Health & Human Services | National Institutes of Health (R01-GM110089)
Chan Zuckerhub Biohub
- License Information
-
More Information
Article History
Received: 16 May 2018
Accepted: 10 April 2019
First Online: 9 May 2019
Competing interests
: C.F. is a co-founder of Mirimus, Inc. B.L.O. is a co-founder and employee of Scribe Therapeutics. D.F.S. is a co-founder of Scribe Therapeutics and a scientific advisory board member of Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribous Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences, and Inari. J.A.D. is a member of the board of directors at Driver and Johnson & Johnson. The remaining authors declare no competing interests.
